New York Hotel Trades Council & Hotel Association of NYC Health Center, Inc.

Company overview. New York Hotel Trades Council & Hotel Association of New York City, Inc., Health Center, Inc. (also identified in filings as the Health Benefits Fund; EIN 13-1595091) is a not-for-profit, jointly trusteed Taft-Hartley employee benefit fund established in 1949 and recognized as a 501(c)(9) voluntary employees' beneficiary association. Headquarters: 305 West 44th St., New York, NY. It is private/non-profit, not publicly traded. Its FY2024 IRS Form 990 reported roughly 1,030 employees, about $294 million in total revenue, and approximately $262 million in total assets.

Operations. The fund provides medical, surgical, pharmaceutical, dental, and ambulatory care to active and retired New York City hotel-industry workers, dependents, and retirees — reportedly covering more than 85,000 participants. Rather than buying insurance, it directly owns and operates Health and Dental Centers in Midtown Manhattan, Harlem, Brooklyn, and Queens, staffs them with its own physicians, dentists, nurses, and pharmacists, and operates on-site pharmacies. It contracts out hospitalization, emergency, and out-of-area care (e.g., via Anthem BlueCross BlueShield) and partners with CityMD for urgent care. It is an operating healthcare provider, not a patent-holding entity.

Patent-litigation posture. The company appears once in the tracked data, as plaintiff (1 plaintiff case, 0 defendant cases), in S.D.N.Y. — there is no NPE-style assertion pattern. Its single suit is an antitrust action touching patents rather than a patent-infringement claim: it alleged monopolization of the pomalidomide (Pomalyst) market via Walker Process fraud, sham litigation, and reverse-payment settlements covering Celgene's pomalidomide patents (e.g., U.S. 8,828,427; 8,673,939; 10,555,939).

Notable case. Health Benefits Fund v. Celgene Corp., No. 1:24-cv-02230-ER (S.D.N.Y., filed Mar. 25, 2024), naming Celgene, Bristol Myers Squibb, Anthony Insogna, and Jerome Zeldis, was consolidated under Louisiana Health Service & Indemnity Co. v. Celgene Corp., No. 1:23-cv-07871-ER, alongside CenterWell Pharmacy, Inc. v. Celgene Corp. The court entered judgment for defendants on April 10, 2026.